Management of Cutaneous Metastasis in Small Cell Lung Cancer
Diagnostic Approach
- The National Comprehensive Cancer Network recommends that if skin biopsy confirms metastatic SCLC, this automatically classifies the patient as extensive-stage disease, fundamentally altering the treatment approach from curative to palliative intent 1, 2
- The Journal of the National Comprehensive Cancer Network suggests that brain MRI (preferred) or CT with contrast is mandatory, as 10-15% of SCLC patients have asymptomatic CNS metastases at diagnosis 5, 2
Staging and Treatment
- The National Comprehensive Cancer Network guidelines state that CT chest and abdomen with IV contrast should be performed to evaluate primary tumor, mediastinal nodes, and abdominal metastases 5, 2, 4
- The American College of Chest Physicians recommends confirm SCLC diagnosis via the least invasive method: sputum cytology, thoracentesis, fine needle aspiration, or bronchoscopy with transbronchial needle aspiration 6
- The National Comprehensive Cancer Network suggests that first-line treatment consists of platinum-etoposide chemotherapy plus immunotherapy for 4-6 cycles, followed by maintenance immunotherapy until progression 3, 4
Prognostic Considerations
- The National Comprehensive Cancer Network guidelines state that adverse prognostic factors include poor performance status (ECOG 3-4), extensive-stage disease, weight loss >5%, elevated LDH, male gender, and age >70 years 3
- The Journal of the National Comprehensive Cancer Network suggests that if cutaneous lymphangitis carcinomatosa is confirmed, this represents extensive-stage disease with median survival of 8-13 months with optimal therapy 2